Moomoo AI 已提取核心訊息
Johnson & Johnson, the New Jersey-based healthcare giant, has announced its definitive agreement to acquire Ambrx Biopharma, Inc., as detailed in a presentation during a town hall with Ambrx employees on February 15, 2024. The acquisition is subject to closing conditions, including antitrust clearances and approval by Ambrx stockholders. Johnson & Johnson cautions that forward-looking statements regarding the acquisition should not be relied upon due to potential risks and uncertainties that could affect the outcome. These include the possibility that the transaction may not be completed as expected, adverse effects on the businesses during the pendency of the transaction, and challenges in integrating Ambrx into Johnson & Johnson's operations. The definitive proxy statement for the proposed transaction was filed with the SEC on January 29, 2024, and mailed to Ambrx stockholders of record as of February 2, 2024. Investors and stockholders are urged to read the relevant documents filed with the SEC for important information about the acquisition.
Johnson & Johnson, the New Jersey-based healthcare giant, has announced its definitive agreement to acquire Ambrx Biopharma, Inc., as detailed in a presentation during a town hall with Ambrx employees on February 15, 2024. The acquisition is subject to closing conditions, including antitrust clearances and approval by Ambrx stockholders. Johnson & Johnson cautions that forward-looking statements regarding the acquisition should not be relied upon due to potential risks and uncertainties that could affect the outcome. These include the possibility that the transaction may not be completed as expected, adverse effects on the businesses during the pendency of the transaction, and challenges in integrating Ambrx into Johnson & Johnson's operations. The definitive proxy statement for the proposed transaction was filed with the SEC on January 29, 2024, and mailed to Ambrx stockholders of record as of February 2, 2024. Investors and stockholders are urged to read the relevant documents filed with the SEC for important information about the acquisition.
總部位於新澤西州的醫療保健巨頭強生公司宣佈了收購Ambrx Biopharma, Inc. 的最終協議，詳情見2024年2月15日在市政廳與Ambrx員工舉行的演講。此次收購受成交條件的約束，包括反壟斷許可和Ambrx股東的批准。強生公司警告說，由於可能影響結果的潛在風險和不確定性，因此不應依賴有關收購的前瞻性陳述。其中包括交易可能無法按預期完成，在交易懸而未決期間對業務造成的不利影響，以及將Ambrx納入強生公司的業務所面臨的挑戰。擬議交易的最終委託書已於2024年1月29日向美國證券交易委員會提交，並郵寄給截至2024年2月2日的Ambrx登記股東。我們敦促投資者和股東閱讀向美國證券交易委員會提交的相關文件，以獲取有關此次收購的重要信息。
總部位於新澤西州的醫療保健巨頭強生公司宣佈了收購Ambrx Biopharma, Inc. 的最終協議，詳情見2024年2月15日在市政廳與Ambrx員工舉行的演講。此次收購受成交條件的約束，包括反壟斷許可和Ambrx股東的批准。強生公司警告說，由於可能影響結果的潛在風險和不確定性，因此不應依賴有關收購的前瞻性陳述。其中包括交易可能無法按預期完成，在交易懸而未決期間對業務造成的不利影響，以及將Ambrx納入強生公司的業務所面臨的挑戰。擬議交易的最終委託書已於2024年1月29日向美國證券交易委員會提交，並郵寄給截至2024年2月2日的Ambrx登記股東。我們敦促投資者和股東閱讀向美國證券交易委員會提交的相關文件，以獲取有關此次收購的重要信息。
有用
沒用